Embracing Diversity & Inclusion
-
Biomarker Testing: A Key Component To Advancing Precision Medicine
9/13/2022
Biomarker testing isn’t always the standard of care for many people living with cancer today. Providers and patients need to be better educated about biomarker testing, we need a consistent standard of care across oncology institutions, and we need to advocate for equitable access to biomarker testing.
-
Genetic Testing For Prostate Cancer Tackles The Black Demographic Disparity
9/9/2022
Inherited factors account for 57% of the risk for developing prostate cancer. Advances in genomic research have an opportunity to improve the health and survival of all men, but the focus of progress has been on people of European ancestry and has excluded Black men, who have a substantially higher incidence of prostate cancer. Genetic testing will help lessen this demographic disparity.
-
3 Strategies For Diverse, Large-Scale Clinical Studies
8/18/2022
Chuanbo Xu of Freenome shares the three strategies that his team used to successfully enroll a diverse patient population across 200 sites for its recent clinical trial.
-
5 Specifications That The FDA’s Diversity Plan Needs To Include
8/16/2022
In April, the FDA released a draft guidance on diversity plans to improve patient enrollment in clinical trials. Tigerlily Foundation believes the FDA's final guidance on the topic needs more teeth.
-
Patient Diversity In Clinical Trials: How To Meet The Need
7/7/2022
The study participants in clinical trials are often homogenous. Although 39% of the U.S. population is composed of people of color, they account for less than 16% of those in clinical trials. Black patients account for only 5% of clinical trial participants in the U.S. This article dives into the topic and shares seven action items for improving diversity.
-
Latin America’s Landscape For Medtech Clinical Trials
7/5/2022
This article examines the need to conduct medtech clinical trials outside the U.S. and explores the growth of these trials in Latin America, particularly in Colombia and Paraguay. It also addresses critical success factors and provides recommendations to ensure cost-effective, ethical, and quality EFS and FIH medtech clinical trials in the region.
-
The Opportunities For Conducting Vaccine Clinical Research In Latin America
6/28/2022
A few decades ago, the development of global clinical research that integrates low- and middle-income countries was considered a dream. Now it is a pressing need. This article discusses the history of vaccine research in Latin America, how the region could help solve the vaccine clinical trial diversity problem in the U.S., and why the region is a desirable destination for such clinical research.
-
Diversity In Clinical Research Execution And Participation
6/27/2022
In this article we compare the 2020 and 2021 result of the WCG Avoca Industry Survey, which explores industry respondents’ views on patient diversity in clinical research participation.
-
Improving Diversity In Clinical Trials With A Community-Based Approach
6/9/2022
Executives of clinical trial sponsors and CROs must acknowledge that the current system fosters inequities such as decreased access and poorer healthcare outcomes for historically underserved patient populations. By committing to a community-based approach to enhance clinical trial diversity, we can further enable improved healthcare outcomes for all.
-
Latin America: A Compelling Region To Conduct Your Clinical Trials
6/7/2022
This article examines the need to conduct clinical trials outside the U.S., addresses the recruitment crisis in the U.S., reviews the incentives for clinical trials overseas, and explores the growth of clinical trials in Latin America. Colombia is highlighted as a country that stands out as ripe with opportunity.